Načítá se...
Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection
In 2016, the US Food and Drug Administration issued a warning about the risk of hepatitis B virus (HBV) reactivation in some patients receiving direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection. HBV reactivation can occur soon after the start of DAA therapy; thus, monitorin...
Uloženo v:
| Vydáno v: | Gastroenterol Hepatol (N Y) |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Millennium Medical Publishing
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5635429/ https://ncbi.nlm.nih.gov/pubmed/29038644 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|